Jazz Pharmaceuticals (JAZZ) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
59.7mn → 61.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
▲2308% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$125.0M returned vs $439.0M of FCF in FY25. Buybacks covered by cash flow.
-8¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 85.8% → 88.2%. Net margin -8.3% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 4,718.2 | 4,267.6 | 4,068.9 | 3,834.2 | 3,659.4 | 3,094.2 | ▲4.9% | +8.4% |
Cost of revenue | 514.6 | 503.3 | 445.7 | 435.6 | 540.5 | 440.8 | ▲12.9% | +3.4% |
Gross profit | 4,203.6 | 3,764.3 | 3,623.2 | 3,398.6 | 3,118.9 | 2,653.5 | ▲3.9% | +9.1% |
Research & development | 1,660.5 | 1,730.6 | 894.0 | 868.7 | 1,034.6 | 505.7 | ▲93.6% | +36.0% |
Selling, general & admin | 1,556.1 | 1,809.3 | 1,385.3 | 1,343.1 | 1,417.0 | 1,451.7 | ▲30.6% | +5.7% |
Total operating expenses | 3,777.6 | 4,194.5 | 2,906.6 | 2,820.0 | 3,184.4 | 2,483.2 | ▲44.3% | +14.0% |
Operating incomefeeds ROC rank | 426.0 | −430.2 | 716.6 | 578.6 | −65.5 | 170.3 | — | — |
Other income, net | −166.1 | −197.6 | −246.3 | −280.7 | −307.3 | −283.1 | — | — |
Pretax income | 259.8 | −627.9 | 470.4 | 297.9 | −372.8 | −112.8 | — | — |
Income tax | 53.7 | −272.4 | −91.4 | −119.9 | −158.6 | 216.1 | ▼198.0% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 206.0 | −356.1 | 560.1 | 414.8 | −224.1 | −329.7 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.07 | −5.84 | 8.65 | 6.10 | −3.58 | −5.52 | — | — |
Diluted shares (mn) | 64.70 | 60.98 | 66.01 | 72.07 | 62.54 | 59.69 | ▼7.6% | +0.5% |
| Margins | ||||||||
Gross margin84th pct in Healthcare | 89.1% | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | ▼0.8pp | +2.5pp |
Operating margin | 9.0% | −10.1% | 17.6% | 15.1% | −1.8% | 5.5% | ▼27.7pp | −15.6pp |
Net margin54th pct in Healthcare | 4.4% | −8.3% | 13.8% | 10.8% | −6.1% | −10.7% | ▼22.1pp | +2.3pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Jazz Pharmaceuticals' revenue last fiscal year?
Jazz Pharmaceuticals reported revenue of $4,267.6M in fiscal 2025, up 4.9% from fiscal 2024.
What was Jazz Pharmaceuticals' net income?
Jazz Pharmaceuticals reported net income of −$356.1M in fiscal 2025, a net margin of −8.3%.

